✦ LIBER ✦

Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma

✍ Scribed by Sumika Saito; Kiyoshi Ito; Satoru Nagase; Takashi Suzuki; Jun-Ichi Akahira; Kunihiro Okamura; Nobuo Yaegashi; Hironobu Sasano

Book ID: 108583764
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 295 KB
Volume: 97
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2006.00332.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

p53 and BCL-2 as Prognostic Markers in E

p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

✍ Márcia L. M. Appel; Maria I. Edelweiss; James Fleck; Luis F. Rivero; Waldemar A. 📂 Article 📅 2008 🏛 Springer Netherlands 🌐 English ⚖ 170 KB

The relationship of COX–2 expression wit

The relationship of COX–2 expression with estrogen receptor, progesterone receptor and prognostic parameters in endometrial carcinomas

✍ Sevinç Hallaç Keser; Aylin Ege Gül; Nagehan Özdemir Barışık; Çağlar Çakır; Sibel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Progesterone Receptor A and B Isoform Ex

Progesterone Receptor A and B Isoform Expression in Human Osteoblasts

✍ P. Mac Namara; H. C. Loughrey 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 299 KB

Growth factors and receptors as prognost

Growth factors and receptors as prognostic markers in urothelial carcinoma

✍ Peter C. Black; Colin P. N. Dinney 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 176 KB

PCNA and Ki-67 as Prognostic Markers in

PCNA and Ki-67 as Prognostic Markers in Human Parathyroid Carcinomas

✍ Kaori Kameyama; Hiroshi Takami; Shinobu Umemura; Yoshiyuki R. Osamura; Nobuyuki 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 974 KB

Ribosomal DNA methylation in patients wi

Ribosomal DNA methylation in patients with endometrial carcinoma : An independent prognostic marker

✍ Matthew A. Powell; David G. Mutch; Janet S. Rader; Thomas J. Herzog; Tim Hui-Min 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 823 KB

## Abstract ## BACKGROUND Surgery is curative for the majority of patients with endometrial carcinoma: Consequently, the use of adjuvant therapy has been controversial. More effective methods to identify patients who are at risk for recurrence and who would benefit from adjuvant therapy are needed